Article Summary

This article reports on a Supreme Court decision allowing the abortion pill mifepristone to remain available by mail, blocking a lower court ruling that threatened that access. It presents arguments from both sides—pharmaceutical companies and abortion rights supporters defending continued access, and Louisiana officials and anti-abortion advocates arguing for in-person requirements—while highlighting the role of federal versus state authority. The article leans on statements from officials and legal figures, using some emotionally charged language, but overall presents a factual account of the ruling and its implications.